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Abstract
Background: Human papillomavirus (HPV) is the necessary cause of cervical cancer. Published data on the
epidemiology of HPV in women with invasive cervical cancer (ICC) in New Zealand (NZ) are limited. This
cross-sectional study investigated the distribution of high-risk and low-risk HPV types in cervical specimens collected
from women throughout NZ who had been diagnosed with ICC between 2004 and 2010.
Methods: Women aged ≥18 years, with ICC International Federation of Gynecology and Obstetrics stage Ib or
greater were identified from the five tertiary public hospitals in NZ regularly treating women with ICC. Women
were enrolled in the study only after obtaining informed consent. Stored, formalin fixed, paraffin-embedded cervical
specimens were retrieved and histopathologically reviewed to confirm the diagnosis of ICC. Cervical specimens
were tested for HPV using polymerase chain reaction-short fragment10; HPV DNA was detected using DNA enzyme
immunoassay and typed by reverse hybridization line probe assay.
Results: 242 women were enrolled and ICC was histologically confirmed in 227 samples. HPV infection was
detected in 88.5% (n = 201; 95% CI: 83.7–92.4) of women with ICC; high-risk HPV types were detected in 87.2% of
women. The most commonly detected HPV types were HPV-16 (51.1%) and HPV-18 (20.7%), followed by HPV-31
(4.0%), HPV-45 and HPV-52 (3.1% each). Overall, HPV distribution was highest (94.3%) in women aged 30–39 years at
diagnosis and a higher distribution of HPV-16 (68.8%) was observed in women younger than 30 years. The overall
distribution of HPV types between Maori and non-Maori women were similar. HPV-positive women with ICC stage II
or greater were less likely to be infected with HPV-16/18 (P = 0.002) or HPV-18 (P = 0.029) compared with the other
high-risk types. Single type infection and multiple infections were detected in 93.5% and 5.5% of women, respectively.
Conclusions: HPV-16, HPV-18, HPV-31, HPV-45 and HPV-52 were the most commonly detected high-risk HPV types.
Findings from the study fill an important data gap on HPV type distribution from NZ which will help facilitate better
understanding of the epidemiology of HPV in NZ women.
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Background
Cervical cancer (CC) is the third most common cancer
in women worldwide with the burden being highest in
developing countries [1]. The incidence of CC in New
Zealand (NZ) and Australia is among the lowest in the
world [2], however CC remains an important, largely pre-
ventable cause of morbidity and mortality and is 3rd most
common among younger women aged 15–44 years [3].
NZ has a population of around 2.18 million women [3]
and the NZ Cancer Registry estimated that there were 141
new CC cases in 2009, 179 in 2010 and 161 in 2011 [4].
The low CC incidence in NZ is in part explained by
the existence of the National Cervical Screening Pro-
gramme (NCSP). Established in 1990, the NCSP recom-
mends cervical smear tests once every three years for
women aged 20–70 years and has been associated with a
marked reduction in the mortality and incidence of CC
[5]. Indigenous populations of NZ, such as Maori wo-
men, have historically had low uptake rates in the NCSP.
In 2006, the NCSP screening coverage was 46.6% for
Maori women compared with 75.7% for non-Maori non-
Pacific women [6]. While much is being done to reduce
the inequalities in healthcare access, CC incidence and
mortality disproportionately affect Maori women [6,7].
In 2009, the age-standardized rate of CC was 10.4 per
100,000 in Maori women compared with 4.8 per 100,000
in non-Maori women [8].
It is well established that persistent infection with
high-risk (HR) human papillomavirus (HPV) is the most
important cause of CC, causing the vast majority of
cases [9]. Fifteen HPV types have been epidemiologically
established as oncogenic or HR: 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68, 73 and 82. A further twelve
types have been classified as low-risk (LR): 6, 11, 40, 42,
43, 44, 54, 61, 70, 72, 81, and CP6108 [10]. HR-HPV types
16 and 18 account for around 70% of all CC cases [11].
As CC is one of the most preventable types of cancer,
even the low incidence rates of CC in NZ are a cause of
concern and these have the potential to be further lo-
wered by comprehensive vaccination initiatives [12,13].
Two HPV vaccines are currently licensed and available in
NZ: the quadrivalent HPV 6/11/16/18 vaccine (Gardasil®,
Merck, US), and the bivalent HPV 16/18 vaccine (Cer-
varix®, GlaxoSmithKline, Belgium) [14,15]. The NZ
Ministry of Health initiated a mass HPV vaccination
programme in 2008, initially for girls from the 1990–1991
birth cohorts. This was subsequently expanded and HPV
vaccination became part of the National Immunization
Schedule for girls aged 12 years in 2009 [15].
Data addressing the epidemiology of HPV among wo-
men with invasive cervical cancer (ICC) in NZ are limited.
As the oncogenicity of specific HPV variants appears to
vary geographically and depending on the ethnic origin of
the population studied [16]. To understand the potential
impact of national HPV vaccine programs on cervical can-
cer incidence baseline epidemiological data are required.
This study aimed to evaluate the prevalence of HPV
types 16 and 18 among women diagnosed with ICC in
NZ, the prevalence of HR and LR HPV types, and co-
infection of HPV-16 and HPV-18 with other HR-HPV
types.
Methods
Study design and population
This cross-sectional, hospital-based, epidemiological stu-
dy was conducted between April 2009 and April 2011 in
the five tertiary hospitals in NZ regularly treating ICC:
National Women’s Hospital (Auckland), Dunedin Hos-
pital (Dunedin), Christchurch Hospital (Christchurch),
Wellington Hospital (Wellington; including cases from
Palmerston North) and Waikato Hospital (Waikato).
Hospital records between 2004 and 2010 were used to
identify women aged 18 years and above with a diagnosis
of ICC International Federation of Gynecology and Ob-
stetrics (FIGO) stage Ib or greater [17]. ICC included all
squamous cell carcinoma (SCC), adenocarcinoma (ADC)
and adenosquamous carcinoma (ASC) types while neu-
roendocrine small cell carcinoma and sarcoma were
excluded. Consent from the patient, or in the case of
deceased patients the next of kin, to access tissue and
clinical notes was obtained. Formalin fixed and paraffin-
embedded cervical tissue samples were then procured
from hospital archives and anonymised. Samples were
excluded if they were too thin (<2 mm), or too small
(<0.5 cm across), or collected from women after chemo-
therapy/radiotherapy. Hospital records were also used
to capture information in the case report form regarding
the demographic characteristics (age, ethnicity), histolo-
gical diagnosis, year of tissue sample collection and the
stage of cancer.
Laboratory procedures
Cervical tissue samples were sectioned using a sandwich
technique and ICC was confirmed in the tissue block by
histopathological review at DDL Diagnostic Laboratory
(Rijswijk, Netherlands). Patients were excluded if ICC
could not be confirmed in the available tissue. HPV
DNA was extracted from histopathologically confirmed
ICC tissue samples using proteinase K and amplified using
the HPV short polymer fragment-10 (SPF10), version 1
polymerase chain reaction (Labo Bio-medical Products,
Rijswijk, The Netherlands). Amplified DNA was detected
with DNA enzyme immunoassay (DEIA) and typed by re-
verse hybridization line probe assay (LiPA, version 1)
using 25 type-specific hybridization probes which detected
14 HR (HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66 and 68) and 11 LR-HPV types (HPV-6, 11, 34, 40, 42,
43, 44, 53, 54, 70 and 74) [18,19]. Positive and negative
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controls were used for each run to monitor DNA isola-
tion, PCR amplification, HPV detection and genotyping.
Re-testing of HPV negative samples was conducted after
diluting DNA tenfold.
Statistical analyses
Based on the global prevalence rates of HPV types in
ICC [20] and allowing for ~ 30% non-evaluable samples,
target enrolment was 285 women to provide 200 sam-
ples evaluable for the prevalence of HPV-16 and HPV-
18 with a precision of ± 7% and ± 5%, respectively.
All analyses were descriptive and the percentage of
women was tabulated with their corresponding exact
95% confidence interval (CI). Exploratory logistic regres-
sion analysis was performed to estimate the effect of age
at sample collection, ethnic origin (Maori/non-Maori)
and stage of cancer (stage Ib/stage II and above) on HPV
detection rate in the histologically confirmed cervical
tissue samples, and also on the prevalence of HPV-16,
HPV-18 and HPV-16/18 in the HPV positive cervical tis-
sue samples. All statistical analyses were performed using
SAS® software version 9.2. (SAS Institute Inc., Cary, NC,
USA).
Ethical considerations
The study was approved by the Health and Disability
Ethics Committees-Multi-Region Ethics Committee,
Wellington, NZ and was conducted in accordance with
the Declaration of Helsinki and Good Clinical Practice
guidelines.
Results
Study population and histopathology
Subject screening and enrolment is summarized in
Figure 1. A total of 242 women were enrolled and the
diagnosis of ICC was histologically confirmed in 227
women. The mean age (standard deviation [SD]) of
women at the time of diagnosis in the histologically
confirmed group was 50.7 (±16.7) years. Women of
Maori ethnicity accounted for 15.0% (34/227) of the
ICC women with the remaining 85.0% (193/227) of non-
Maori origin.
Of the 227 confirmed ICC cases, 159 (70.0%) were
SCC, 61 (26.9%) ADC and 7 (3.1%) ASC. A total of 115
out of 227 women (50.1%) were assessed as having FIGO
stage Ib cancer while the remaining 112 were diagnosed
with cancer of FIGO stage II and above.
Overall HPV detection rate and type distribution
The overall detection rate and type distribution of HPV
are shown in Table 1. HPV DNA was detected in 88.5%
(201/227) of histologically confirmed ICC tissue samples,
with 93.1% (148/159) SCC and 77.9% (53/68) of ADC/
ASC positive for HPV. Among HPV positive samples,
81.1% (163/201) were infected with either HPV 16 or 18.
The most common HR HPV types detected among con-
firmed ICC cases were HPV-16 (51.1%) and HPV-18
(20.7%). HPV-16 was the most prevalent HPV DNA type
across the ICC histological subtypes, but HPV-18 was
detected in proportionally more ADC/ASC than SCC
(35.3% vs. 14.5%). For the LR HPV types detected, HPV-
11 and HPV-70 were detected in one cervical sample
each and were both of the SCC subtype.
HPV detection rate and type distribution by age
The HPV detection rate and type distribution of HPV by
age group is shown in Figure 2. The distribution of any
HPV type was highest in women aged 30–39 years at
diagnosis. HPV-16 was detected more frequently in wo-
men aged less than 30 years compared with those aged
greater than 30 years.
HPV detection rate and type distribution by ethnicity
HPV detection rate among Maori and non-Maori wo-
men is shown in Table 2. The detection rate of HPV in
the confirmed ICC samples was similar in the two ethnic
groups with 88.2% and 88.6% of cervical tissue samples
positive for HPV from Maori and non-Maori women
respectively. No significant associations were found bet-
ween ethnicity and either HPV detection rate, histological
subtype or stage of cancer. Additionally, no statistically
significant difference was seen in the age at diagnosis be-
tween Maori and non-Maori women (Table 2).
The prevalence of individual HPV type by ethnicity is
shown in Figure 3. Infection with any HR HPV type was
similar in Maori (85.3%, 29/34) and non-Maori (87.6%,
169/193) women. HR HPV-16 was present in 58.8%
(20/34) Maori women and 49.7% (96/193) non-Maori
women. HR HPV-18 was present in 11.8% (4/34) Maori
women and 22.3% (43/193) non-Maori women. Minor
Figure 1 Subject screening and enrolment. *Reasons included:
subjects contacted by other study site (n = 6); uncertain diagnosis
(n = 1) and not specified (n = 1). ICC, invasive cervical cancer.
Sykes et al. BMC Infectious Diseases 2014, 14:374 Page 3 of 9
http://www.biomedcentral.com/1471-2334/14/374
variations in HPV type distribution were observed in the
HPV non-16/-18 types between the two ethnic groups.
HPV detection rate and type distribution by stage
of cancer
Among HPV positive cases (201/227), women with FIGO
cancer stage II and above were less likely to be infected
with HPV-16/18 compared with women who had FIGO
cancer stage Ib when adjusted for ethnicity (adjusted odds
ratio 0.3, 95% CI: 0.1–0.6; P = 0.002). Similarly, women
with FIGO cancer stage II and above were less likely to be
infected with HPV-18 compared with women who had
FIGO cancer stage Ib when adjusted for ethnicity (ad-
justed odds ratio 0.5, 95% CI: 0.2–0.9; P = 0.029). The
Table 1 HPV detection and type distribution in histologically confirmed ICC tissue samples from New Zealand
women (Na = 227)
Histological
diagnosis/HPV type
All ICC types (N = 227) ICC subtypes
ADC/ASC (N = 68) SCC (N = 159)
nb %c (95% CI) n % (95% CI)d n % (95% CI)
HPV positive 201 88.5 (83.7–92.4) 53 77.9 (66.2–87.1) 148 93.1 (88.0–96.5)
Any high-risk HPV 198 87.2 (82.2–91.3) 53 77.9 (66.2–87.1) 145 91.2 (85.7–95.1)
HPV-16 116 51.1 (44.4–57.8) 27 39.7 (28.0–52.3) 89 56.0 (47.9–63.8)
HPV-18 47 20.7 (15.6–26.6) 24 35.3 (24.1–47.8) 23 14.5 (9.4–20.9)
HPV-31 9 4.0 (1.8–7.4) 0 0.0 (0.0–5.3) 9 5.7 (2.6–10.5)
HPV-45 7 3.1 (1.2–6.3) 2 2.9 (0.4–10.2) 5 3.1 (1.0–7.2)
HPV-52 7 3.1 (1.2–6.3) 0 0.0 (0.0–5.3) 7 4.4 (1.8–8.9)
HPV-59 5 2.2 (0.7–5.1) 0 0.0 (0.0–5.3) 5 3.1 (1.0–7.2)
HPV-33 4 1.8 (0.5–4.5) 1 1.5 (0.0–7.9) 3 1.9 (0.4–5.4)
Other 17* 7.5 (4.4–11.7) 1 1.5 (0.0–7.9) 16 10.1 (5.9–15.8)
Any low-risk HPV 2 0.9 (0.1–3.1) 0 0.0 (0.0–5.3) 2 1.3 (0.2–4.5)
anumber of women with the corresponding diagnosis.
bnumber of women in each category.
cpercentage of women in each category.
dexact 95% confidence interval.
ICC: Invasive cervical cancer; ADC: Adenocarcinoma; ASC: Adenosquamous carcinoma; SCC: Squamous cell carcinoma.
*Includes 2 HPV types unidentifiable by LiPA.
Other refers to HPV-35 (3 ICC samples), 39 (3), 51 (2), 56 (3), 66 (1), 68 (3) and –X (2 HPV types unidentifiable by LiPA).
Figure 2 Prevalence of HPV types by age at diagnosis in histologically confirmed ICC tissue samples from New Zealand women (N = 227).
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adjusted odds ratio for HPV-16 was not statistically sig-
nificant (0.8, 95% CI: 0.6–1.4; P = 0.477).
Co-infection with multiple HPV types
The prevalence of co-infection with multiple HPV types
is shown in Table 3. The majority (93.5%, 188/201) of
HPV positive women with ICC were infected with a sin-
gle HPV type. Multiple HPV type infections were found
in 5.5% of women, while in a further 1.0% of the HPV-
positive samples the HPV type were unidentifiable by
the typing test. Co-infections were more commonly found
in SCC (6.1%) than in ADC/ASC (3.8%).
Discussion
This is the first study attempting to estimate the nation-
wide type distribution of HPV among NZ women diag-
nosed with ICC. Evidence of HPV infection was found
in 88.5% of the histologically-confirmed ICC cases, and
consistent with previous studies was higher in SCC than
ADC/ASC cases. The majority (87.2%) were infected
with HR HPV types. The distribution of HPV infection
was highest in women aged 30–39 years. Since compre-
hensive data on the detection rate and type distribution
of HPV among women with ICC in NZ are lacking, this
study adds important information to this field.
Our findings on HPV detection rates are comparable
with reports from the NZ region, Australia and interna-
tional data. A single-region study (Auckland, NZ; 2000–
2006) of 50 cervical biopsy specimens from women with
confirmed ICC, reported 100% HPV infection and a 83.6%
prevalence of HR HPV-16 and 18 [21]. Another study of
HPV prevalence in liquid based cytology specimens of 594
patients from the NZ-NCSP referred for colposcopy with
high grade cervical lesions between 2009 and 2011, re-
ported a HR HPV prevalence of 86.7% [22]. An inter-
national study including 10 575 cases of ICC from around
the world including Australia but not NZ, reported that
85.0% of the women with ICC were HPV positive [11]. A
recent meta-analysis with Oceania data from nine studies
found that HPV prevalence varied substantially by region
Table 2 Comparison of Maori and non-Maori women with






nb (%c) n (%)
By age at
diagnosis*
Mean (SDe) 48.7 (13.5) 51.5 (17.2) 0.507




ADC/ASC 9 (26.5) 59 (30.6) 0.630
SCC 25 (73.5) 134 (69.4)
By cancer stage# Stage Ib 16 (47.1) 99 (51.3) 0.649
Stage II and above 18 (52.9) 94 (48.7)
anumber of women with the corresponding diagnosis.
bnumber of women in each category.
cpercentage of women in each category.
dFisher’s Exact test for HPV prevalence in each histological diagnosis; Wilcoxon
2-Sample Test for age at diagnosis, Chi-square test for histological diagnosis
and cancer stage.
estandard deviation.
#Hypothesis tested any association between the features and the ethnic groups.
*Hypothesis tested any significant difference with respect to age between the
ethnic groups.
Figure 3 Prevalence of HPV types by ethnic group (Maori or non-Maori) in histologically confirmed tissue samples (N = 227).
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among women with normal cytology but was consistent at
about 90% for ICC across all regions [23].
The HPV type distribution results from our study
show that HPV-16 and HPV-18 were the most common
HR HPV types. This is consistent with previous litera-
ture from the region [22,24-26] and globally [11]. In ad-
dition, the frequently detected non-16/18 HR HPV types
in our study were HPV-31, 45, 52, 59 and 33 which is
consistent with existing international data [23,26], data
from Australia [27] and with recent data from NZ in high
grade cervical intraepithelial neoplasia [22]. It is interest-
ing to note that in the cytology based study, HPV-52 was
found in 21% of NZ women with CIN3 compared with 3%
of women with ICC in our study [22]. These findings
highlight the importance of future monitoring of HPV
genotypes in women with cervical cancer and the screen-
ing population.
Epidemiological studies of HPV type distribution in
SCC and ADC conducted in Oceania and world-wide re-
port that the prevalence of HPV-16 is higher in SCC
while HPV-18 is more predominantly seen in ADC/ASC
cases [11,26,28]. We also observed a similar trend with
HPV-16 being present in 56% of SCC cases compared
with 39.7% in ADC/ASC cases, and HPV-18 present in
35.3% of ADC/ASC cases compared with only 14.5% of
SCC cases. However, more recent studies indicate that
HPV-16 and -18 constitute more than 80% of HPV types
detected in women with cervical ADC [29,30].
Of particular interest, we found that HPV-16 was de-
tected more frequently in women aged < 30 years than in
other age groups, which is in accordance with previous
studies [11,31-34]. The highest relative prevalence of
type 16/18 versus other HR HPV types was also reported
recently among women aged 20–29 years in a study
among women with high grade cervical intraepithelial
lesions [23]. We also found a lower proportion of HPV
16/18 or HPV 18 positive cases in advanced stage dis-
ease. There is little published information regarding the
correlation of HPV type and cancer stage.
The reasons for these trends are unclear. More ad-
vanced disease is progressively common in older women.
It is possible that 16/18 types are simply more prevalent
in younger women, HPV may be less well preserved or
expressed in more advanced tumours, or differences in
the tumour biology may be important. One explanation
may be that HPV types 16, 18 and 45 are more likely to
be integrated into the human genome compared with
other types and as a result have a more rapid natural his-
tory in episomal form, resulting in detection at a younger
age or earlier stage of cancer. As younger women are bet-
ter screened they may present at earlier stage of cervical
abnormality [34]. Further investigation of these matters is
warranted, as they may help inform the design of future
screening (cervical smear or HPV DNA testing) or vaccin-
ation programs.
Ethnicity and its associations with HPV type distri-
bution were assessed, although this was not the primary
objective and the study was not sufficiently powered to
test any hypothesis around this. It has been estimated
that Maori women have an approximately 2-fold higher
incidence of ICC [35]. For the years 1991–2004, Maori wo-
men with CC had a 61% greater excess mortality (poorer
survival) compared with non-Maori women [8]. However,
no differences in ICC subtype distribution and stage of
cancer were observed between Maori and non-Maori wo-
men with ICC. Only minor variations in non HPV-16/18
types were observed between the Maori and non- Maori
women. Our epidemiological findings do not explain the
existence of the higher incidence or mortality burden in
Table 3 Co-infection of HPV types among HPV positive
ICC tissue samples from New Zealand women (Na = 201)
Histological diagnosis HPV types nb %c
All ICC
N = 201 Any single infection 188 93.5











Unidentifiable HPV infection 2 1.0
ICC subtypes
ADC/ASC Any multiple HPV types 2 3.8
N = 53 16/18 1 1.9
18/35 1 1.9
SCC Any multiple HPV types 9 6.1








anumber of women with the corresponding diagnosis.
bnumber of women in each category.
cpercentage of women in each category.
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Maori women compared with non-Maori women. The
slightly higher proportion of Maori women with HPV-16
infection in this study might be expected with the younger
age, lower screening rate and higher SCC rates reported
previously in this group.
An earlier study from Auckland, NZ, found that the
prevalence of multiple HPV type infections among ICC
is 14.2% [22] compared with the 5.5% reported in our
study. This discrepancy may be explained by technological
differences in the technique used for DNA extraction and
HPV typing between studies, selection and size of tissue
samples, complexity of the lesions, or real differences in
the populations investigated. Multiple infections with dif-
ferent HPV types in the genital tract are not uncommon,
with lower grade squamous lesions adjacent to the tumour
often present in ICC tissue sections.
Our study has several strengths. It is the first national
study reporting representative and recent data among
women with ICC in NZ. The majority of the CC treat-
ment in NZ is performed by or in conjunction with the
public hospitals regularly treating ICC. Therefore, as CC
treatment of women with FIGO stage Ib or greater is
centralized to the participating hospitals in the study,
the study design offered good representativeness of the
population. Moreover, the cervical tissue samples were
tested in a central laboratory providing a uniform diagnos-
tic approach with standardized process of sample hand-
ling, HPV DNA detection and type identification using a
highly sensitive assay.
The limitations of this study include the large number
of screened women who were not included in the study,
the lack of access to original tissues by the reviewing pa-
thologists, variable quality of paraffin embedded tissue
samples and self reporting of ethnicity which might have
led to misclassification. Furthermore, since we did not
include DNA controls to further test the HPV negative
samples, some of the HPV negative samples might be
false negatives. The detection rate in this study might
therefore underestimate the true prevalence of HPV.
The study aimed to be representative of all women
with ICC in New Zealand. Due to ethical requirements
all women or their next of kin had to give informed con-
sent for the samples to be included in the study and as a
result only 242 of 402 screened women were enrolled.
This has the potential to bias the study inclusion on
socioeconomic, geographical, age ethnicity and disease
status. While the age range of women included in this
analysis is comparable with national cervical cancer re-
gistration figures, only 15% of women were Maori, slightly
lower than in cancer registration figures and suggesting
this group is slightly underrepresented here. While these
matters must be remembered when drawing conclusions
from this cross-sectional study the authors believe this is
the most accurate possible assessment of HPV detection
rate in NZ women with ICC prior to the introduction of
the HPV vaccination program.
Patients with FIGO stage 1a were excluded as stage 1a
tumours would be less likely to have available material due
to serial sectioning of tumour for diagnostic reasons and
referral to tertiary centres could not be guaranteed. The
study is therefore not representative for this group. Finally,
while cross-sectional study designs are widely accepted and
utilised, the results only reflect a single time point estima-
tion meaning HPV types cannot be linked to outcomes.
Despite these limitations, the study reports recent epi-
demiological data which can facilitate future policy and
strategy decisions for HPV vaccination programmes and
cervical screening in NZ.
Currently, the vaccination programme in NZ is poorly
attended. Of the girls from the 1992 birth cohort (whose
eligibility for free vaccination expired in 2012), only 51%
completed the three-dose schedule for the quadrivalent
HPV vaccine [12]. Australia, one of the first countries to
introduce a national immunization program in 2007 has
good coverage rates with 73% of school-aged girls having
received all three doses of the vaccine [36].
Considering that women from poorer socioeconomic
groups, Maori and other ethnicities have lower utilization
of screening, more will need to be done to drive the up-
take of screening as well as immunization in these groups
to ensure equitable benefits and reduce the morbidity and
mortality due to HPV.
Conclusion
Findings from the study fill an important gap in epidemio-
logical data on HPV type distribution in ICC patients
from NZ which will help facilitate better understanding of
the potential impact of HPV vaccines on the prevention of
CC in NZ women, especially vaccines that provide broa-
der protection beyond HPV-16/18.
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